This post was originally published by Myasthenia Gravis News A 60-year-old man being treated for multiple myeloma was found to have myasthenia gravis (MG) caused by antibodies against muscle-specific tyrosine kinase (MuSK), a study reports. This unusual case indicates that cancer treatments may mask the symptoms of MG, complicating diagnosis, researchers said. The case was described in the journal BMC Neurology,...Continue Reading
This was originally posted by Cision PR Newswire SALT LAKE CITY, July 9, 2020 /PRNewswire/ — HealthTree®, the first online portal for multiple myeloma cancer patients to find their best treatment options and help accelerate a cure, today announced the launch of HealthTree University (HTU), the first comprehensive resource that empowers multiple myeloma patients to become experts in...Continue Reading
This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on clinical hold following the submission of a patient’s safety report. The FDA placed the MELANI-01 trial on hold following the submission of a safety report, according to a Cellectis press release. The safety report...Continue Reading
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple myeloma. Although stem cell mobilization is successful in the majority of patients with multiple myeloma, the use of granulocyte colony-stimulating factor (G-CSF) used alone is associated with up to a 10% failure rate, Kumar explains....Continue Reading
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according to data from a Phase 3 trial. “There is a strong need for additional maintenance treatments for multiple myeloma, where currently approved options are limited,” Meletios Dimopoulos, MD, the trial’s...Continue Reading
This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment regimen combining Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone on the Pharmaceutical Benefits Scheme (PBS). Known as triplet therapy, each drug in the combination has a different mechanism of action to kill myeloma cells, and all work...Continue Reading
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have unveiled the first in silico multiple myeloma patient. Called Gemini, the in silico multiple myeloma patient is a computer model of disease progression and drug response at the individual patient level. The company says Gemini has multiple...Continue Reading
A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.Continue Reading
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin...Continue Reading
A series of molecular abnormalities in smoldering multiple myeloma that are independent predictors of progression to multiple myeloma were accurately identified in a genomic test of bone marrow tissue, according to a study led by researchers at the Dana-Farber Cancer Institute and published in the Journal of Clinical Oncology.1,2 Patients identified with these alterations can be closely...Continue Reading
